title: Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy.
abstract: OBJECTIVE
  To compare clinical outcomes among patients with acute coronary syndrome treated with zotarolimus-eluting and sirolimus-eluting stents in the SORT OUT III trial.
  
  
  BACKGROUND
  Currently, only limited data allow direct comparison of clinical outcomes among patients with acute coronary syndrome treated with a second-generation drug-eluting stent (DES) eluting zotarolimus vs. a first-generation DES eluting sirolimus.
  
  
  METHODS
  Patients with acute coronary syndrome (n=1052) were randomized to treatment with zotarolimus-eluting (n=506) or sirolimus-eluting (n=546) stents and followed for 18 months. The primary composite endpoint, major adverse cardiac events (MACE), was defined as a composite of cardiac death, myocardial infarction or target vessel revascularization.
  
  
  RESULTS
  Zotarolimus-eluting stent treatment compared to sirolimus-eluting stent treatment was associated with increased rates of MACE (8·7% vs. 5·0%; hazard ratio (HR), 1·78; 95% confidence interval (CI), 1·10-2·88; P=0·02) and TVR (6·8% vs. 3·9%; HR, 1·77; 95% CI, 1·03-3·04; P=0·04), while all-cause death, cardiac death, myocardial infarction and definite stent thrombosis did not differ significantly. In the same trial, stable angina pectoris patients (n=1206) were randomized to zotarolimus-eluting (n=614) and sirolimus-eluting (n=592) stents with similar results.
  
  
  CONCLUSIONS
  With and without acute coronary syndromes, patients treated with the sirolimus-eluting stent had better clinical outcomes than those treated with the zotarolimus-eluting stent.
authors.affiliation: Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark. troels.thim@ki.au.dk
authors.forename: Troels
authors.initials: T
authors.lastname: Thim
authors.forename: Michael
authors.initials: M
authors.lastname: Maeng
authors.forename: Anne
authors.initials: A
authors.lastname: Kaltoft
authors.forename: Lisette O
authors.initials: LO
authors.lastname: Jensen
authors.forename: Hans H
authors.initials: HH
authors.lastname: Tilsted
authors.forename: Peter R
authors.initials: PR
authors.lastname: Hansen
authors.forename: Henning
authors.initials: H
authors.lastname: Kelbaek
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.forename: Jan
authors.initials: J
authors.lastname: Ravkilde
authors.forename: Morten
authors.initials: M
authors.lastname: Madsen
authors.forename: Henrik T
authors.initials: HT
authors.lastname: Sørensen
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: Jens F
authors.initials: JF
authors.lastname: Lassen
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D060050:Angina, Stable / Q000188:drug therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D020123:Sirolimus / Q000008:administration & dosage* / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; C489443:zotarolimus; D020123:Sirolimus